Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib and Rituximab in Previously Untreated Low and Intermediate Risk Mantle Cell Lymphoma
NCT06263491Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pirtobrutinib in mantle cell lymphoma (MCL) (2 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Objective Response Rate and Safety and Adverse Events. Started May 2024; status: recruiting.
02
Drugs
pirtobrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06263491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06263491.